Richard Malamut

Articles

Teva is looking to evolve its business through new R&D programmes and development of 'New Therapeutic Entities' from off-patent drugs.

News

BioNTech's vaccine for head and neck cancer has failed a clinical trial, but it will wait for more data before deciding the programme's fate.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.